Luye Pharma Group (LUP) Stock Price & Analysis
LUP Stock Chart & Stats
- Day’s Range
- EUR 0.18 - EUR 0.18
- 52-Week Range
- EUR 0.18 - EUR 0.35
- Previous Close
- EUR 0.18
- Volume
- 0
- Average Volume (3M)
- 0
- Market Cap
- EUR 708.25M
- Enterprise Value
- EUR 9.44B
- Total Cash (Recent Filing)
- EUR 10.76B
- Total Debt (Recent Filing)
- EUR 12.54B
- Price to Earnings (P/E)
- 7.7
- Beta
- 0.84
- Next Earnings
- Mar 31, 2027 (Est.)
- EPS Estimate
- 0.01
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- N/A
Bulls Say, Bears Say
Bulls Say
Strong Profitability
High gross, operating, and EBITDA margins indicate a profitable specialty-pharmaceutical platform with meaningful operating economics. This profitability can support continued investment in product development, commercialization, and lifecycle management while providing resilience against moderate cost or pricing pressure.
Improving Balance Sheet
Lower leverage and a larger equity base improve financial flexibility and reduce balance-sheet strain compared with earlier years. This gives Luye more capacity to fund research, product launches, and commercialization while limiting the impact of debt obligations on future execution.
Operating Cash Flow Rebound
The return to positive operating and free cash flow demonstrates that the business generated cash after the prior-year setback. If maintained, this can provide internally funded support for pipeline investment, debt management, and shareholder returns without relying as heavily on external financing.
Bears Say
Sharp Revenue Contraction
The steep revenue decline raises concerns about the durability of demand and the stability of the current profit base. Even with healthy margins, weaker sales can reduce operating leverage, limit reinvestment capacity, and make future earnings more dependent on successful product recovery or new launches.
Volatile Free Cash Flow
Repeated periods of negative free cash flow and only moderate conversion in 2025 indicate that accounting profitability has not translated consistently into distributable cash. This variability can constrain reliable funding for pipeline development and make long-term capital allocation less predictable.
Low Return On Equity
A low return on equity suggests the enlarged capital base is producing limited bottom-line efficiency relative to the resources invested. Unless profitability improves or assets are used more productively, this may restrict sustainable value creation and weaken the effectiveness of future reinvestment.
Luye Pharma Group News
LUP FAQ
What was Luye Pharma Group’s price range in the past 12 months?
What is Luye Pharma Group’s market cap?
When is Luye Pharma Group’s upcoming earnings report date?
How were Luye Pharma Group’s earnings last quarter?
Is Luye Pharma Group overvalued?
Does Luye Pharma Group pay dividends?
What is Luye Pharma Group’s EPS estimate?
How many shares outstanding does Luye Pharma Group have?
What happened to Luye Pharma Group’s price movement after its last earnings report?
Which hedge fund is a major shareholder of Luye Pharma Group?
What is the TipRanks Smart Score and how is it calculated?
Company Description
Luye Pharma Group
Luye Pharma Group Ltd. functions as a global investment holding enterprise, focusing on the worldwide development, production, marketing, and sales of pharmaceutical products. The company's diverse portfolio includes several key oncology treatments: Lipusu for ovarian and breast cancers; CMNa, a chemical sensitizer used in cancer radiotherapy; Tiandida, targeting ovarian or non-small cell lung cancer; and Boyounuo, an injectable medication for various cancers and solid tumors. It also offers Yitaida for acute promyelocytic leukemia and liver cancer, and Lutingnuo, a glutathione injection for combating toxicity and injuries from ionizing radiation. Tiandixin serves as an adjuvant therapy for malignant tumors, hydrothorax, ascites, and respiratory infections. In the metabolic and cardiovascular health sector, Luye Pharma provides Xuezhikang, a lipid-regulating drug for hypercholesterolemia; Beitangning, a pioglitazone hydrochloride capsule for blood glucose control; and Beixi, an acarbose capsule for Type 2 diabetes. For neurological conditions and pain management, offerings include Maitongna, indicated for cerebral edema caused by trauma or surgery, and for venous reflux disorders. Transdermal patches such as Rivastigmine are available for Alzheimer's disease, Fentanyl for cancer pain, and Buprenorphine for chronic pain relief. Additionally, Seroquel and Seroquel XR are provided for treating schizophrenia and manic episodes associated with bipolar affective disorders. Rykindo, an injection for schizophrenia, is also part of their neurological therapeutics. Further therapeutic solutions span various conditions: Nuosen for acute upper digestive tract hemorrhage; Sailimai for diarrhea treatment; and the Apleek Transdermal Patch for contraception. Addressing musculoskeletal and inflammatory issues, the company offers Sidinuo for osteoporosis, Glucosamine hydrochloride tablets for osteoarthritis, Oulai (a compound sodium aescinate gel) for localized swelling, Oukai for soft tissue swelling and venous edema, and Fengshiye for pain in bones, joints, and limbs. Beyond product development, Luye Pharma Group actively engages in the distribution and commercialization of its pharmaceutical drugs, along with the manufacturing and sale of biopharmaceutical products. The company was established in 1994 and is headquartered in Yantai, People's Republic of China.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- CEO
- Dian Bo Liu
- Employees
- 5,270
- Website
- www.luye.cn
- Address
- No. 15 Chuang Ye Road, Yantai, GD, 264003, CN
Luye Pharma Group (LUP) Earnings & Revenues
LUP Stock 12 Month Forecast
Average Price Target
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 5 | 2 | 15 |
| Technical Analysis | 5 | 2 | 3 |
| Moving Averages | 0 | 0 | 12 |